Literature DB >> 2342972

Doxorubicin-associated flare reactions.

C F Curran, J K Luce, J A Page.   

Abstract

An analysis was made of 539 cases of venous flare reactions associated with the administration of doxorubicin. These reactions always were nondebilitating and generally were transient with complete resolution occurring within 45 minutes of onset in 462 patients (86%). Local urticaria occurred in 133 patients (25%), and 35 patients (6%) reported either vein pain or a stinging sensation. In 20 cases (4%), erythema in the region immediately surrounding the infusion site accompanied the primary manifestation of erythema along the course of the vein proximal to the infusion site. The incidence of initial flare reactions peaked in the autumn months. These reactions frequently occurred at clinical sites in sporadic clusters. Clinical features are described that differentiate flare reactions from early extravasations of doxorubicin. Procedures for minimizing the possibility of the occurrence or reappearance of flare reactions are suggested.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2342972

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  4 in total

1.  Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients.

Authors:  Yoichiro Yoshida; Seiichiro Hoshino; Naoya Aisu; Masayasu Naito; Syu Tanimura; Ai Mogi; Toshihiro Tanaka; Keiji Hirata; Kazuo Tamura; Yuichi Yamashita
Journal:  Int J Clin Oncol       Date:  2014-05-10       Impact factor: 3.402

2.  Effect of corticosteroids on phlebitis induced by intravenous infusion of antineoplastic agents in rabbits.

Authors:  Emiko Kohno; Saori Murase; Kenji Matsuyama; Noboru Okamura
Journal:  Int J Med Sci       Date:  2009-08-06       Impact factor: 3.738

Review 3.  Aloe vera for prevention and treatment of infusion phlebitis.

Authors:  Guo Hua Zheng; Liu Yang; Hai Ying Chen; Jian Feng Chu; Lijuan Mei
Journal:  Cochrane Database Syst Rev       Date:  2014-06-04

4.  A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.

Authors:  Yoichiro Yoshida; Keiji Hirata; Hiroshi Matsuoka; Shigeyoshi Iwamoto; Masahito Kotaka; Hideto Fujita; Naoya Aisu; Seiichiro Hoshino; Takeo Kosaka; Kotaro Maeda; Fumiaki Kiyomi; Yuichi Yamashita
Journal:  Drug Des Devel Ther       Date:  2015-11-11       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.